Polysaccharide and uses thereof

Patent metadata

Field	Value
Publication number	US-12214029-B2
Application number	US-202318305948-A
Country	US
Kind code	B2
Filing date	Apr 24, 2023
Priority date	Feb 24, 2014
Publication date	Feb 4, 2025
Grant date	Feb 4, 2025

Abstract

Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

First claim

What is claimed is:

1. A pharmaceutical composition comprising a glycoconjugate of an E. coli O25B antigen covalently coupled to a carrier protein, wherein the E. coli O25B antigen comprises the structure of Formula O25B′:

wherein n is an integer of 1 to 30; and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , wherein the carrier protein is selected from the group consisting of detoxified Exotoxin A of P. aeruginosa (EPA), CRM197, maltose binding protein (MBP), Diphtheria toxoid, Tetanus toxoid, detoxified hemolysin A of S. aureus , clumping factor A, clumping factor B, E. coli FimH, E. coli FimHC, E. coli heat labile enterotoxin, detoxified variants of E. coli heat labile enterotoxin, Cholera toxin B subunit (CTB), cholera toxin, detoxified variants of cholera toxin, E. coli Sat protein, the passenger domain of E. coli Sat protein, Streptococcus pneumoniae Pneumolysin and detoxified variants thereof, C. jejuni AcrA, and C. jejuni natural glycoproteins.

3. The pharmaceutical composition of claim 2 , wherein the carrier protein is detoxified EPA or CRM197.

4. The pharmaceutical composition of claim 1 , wherein the E. coli O25B antigen is covalently coupled to an Asn residue in the carrier protein.

5. The pharmaceutical composition of claim 4 , wherein the Asn residue of the carrier protein is positioned in the consensus sequence Asp (Glu)-X-Asn-Z-Ser(Thr), wherein X and Z are independently selected from any natural amino acid except Pro (SEQ ID NO:15).

6. The pharmaceutical composition of claim 1 , further comprising a conjugate of an E. coli O1 antigen covalently coupled to a carrier protein, a conjugate of an E. coli O2 antigen covalently coupled to a carrier protein, and a conjugate of an E. coli O6 antigen covalently coupled to a carrier protein.

7. The pharmaceutical composition of claim 6 , wherein the E. coli O1 antigen comprises the structure of Formula O1A′:

the E. coli O2 antigen comprises the structure of Formula O2′:

and
the 06 antigen comprises the structure of Formula 06GlcNAc′:

wherein n is an integer of 1 to 30.

8. The pharmaceutical composition of claim 1 , wherein the glycoconjugate of the E. coli O25B antigen is a bioconjugate.

9. The pharmaceutical composition of claim 8 , wherein the carrier protein is detoxified EPA.

10. The pharmaceutical composition of claim 9 , wherein the E. coli O25B antigen is covalently coupled to an Asn residue in the carrier protein, wherein the Asn residue of the carrier protein is positioned in the consensus sequence Asp (Glu)-X-Asn-Z-Ser(Thr), wherein X and Z are independently selected from any natural amino acid except Pro (SEQ ID NO:15).

11. The pharmaceutical composition of claim 1 , further comprising an adjuvant.

12. The pharmaceutical composition of claim 8 , further comprising an adjuvant.

13. A method of inducing an immune response in a subject against extra-intestinal pathogenic Escherichia coli comprising administering to the subject an effective amount of the pharmaceutical composition of claim 1 .

14. A composition comprising a conjugate of an E. coli O25B polysaccharide antigen covalently coupled to an Asn residue in a carrier protein.

15. The composition of claim 14 , wherein the Asn residue of the carrier protein is positioned in the consensus sequence Asp (Glu)-X-Asn-Z-Ser(Thr), wherein X and Z are independently selected from any natural amino acid except Pro (SEQ ID NO:15).

16. The composition of claim 14 , wherein the carrier protein is detoxified Exotoxin A of P. aeruginosa.

17. The composition of claim 14 , further comprising a conjugate of an E. coli O1 antigen covalently coupled to a carrier protein, a conjugate of an E. coli O2 antigen covalently coupled to a carrier protein, and a conjugate of an E. coli O6 antigen covalently coupled to a carrier protein.

18. A pharmaceutical composition comprising the composition of claim 14 , and a pharmaceutically acceptable carrier.

19. A method of inducing an immune response in a subject against extra-intestinal pathogenic Escherichia coli comprising administering to the subject an effective amount of the pharmaceutical composition of claim 18 .

20. A method of producing a pharmaceutical composition comprising the step of combining:
a) an E. coli O25B glycoconjugate comprising an O25B′ antigen covalently joined a carrier, wherein the O25B′ antigen has the structure:

wherein n is an integer of 1 to 30; and
b) a pharmaceutically acceptable carrier.

Assignees

• Glaxosmithkline Biologicals Sa

Inventors

• Kowarik Michael T
• Wetter Michael L
• Kemmler Stefan J
• Häuptle Micha A
• Gambillara Veronica
• Mally Manuela

Classifications

• C07K14/21

  from Pseudomonadaceae (F) · CPC title

• A61K2039/70

  Multivalent vaccine · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K47/646

  the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines · CPC title